FALLACARA, ANNA LUCIA
 Distribuzione geografica
Continente #
NA - Nord America 1.254
EU - Europa 857
AS - Asia 149
SA - Sud America 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.264
Nazione #
US - Stati Uniti d'America 1.252
GB - Regno Unito 302
IE - Irlanda 181
IT - Italia 115
CN - Cina 108
SE - Svezia 75
UA - Ucraina 73
FR - Francia 43
DE - Germania 32
FI - Finlandia 14
VN - Vietnam 11
TR - Turchia 7
CZ - Repubblica Ceca 6
ES - Italia 4
IN - India 4
JP - Giappone 4
NL - Olanda 4
RU - Federazione Russa 4
SG - Singapore 4
IR - Iran 3
AE - Emirati Arabi Uniti 2
BE - Belgio 2
BR - Brasile 2
CA - Canada 2
BD - Bangladesh 1
BO - Bolivia 1
EU - Europa 1
HK - Hong Kong 1
IL - Israele 1
IQ - Iraq 1
JO - Giordania 1
PH - Filippine 1
PT - Portogallo 1
RO - Romania 1
Totale 2.264
Città #
Southend 282
Fairfield 196
Dublin 177
Chandler 108
Woodbridge 102
Ashburn 88
Siena 88
Houston 87
Seattle 85
Wilmington 81
Jacksonville 70
Cambridge 68
Menlo Park 63
Ann Arbor 34
New York 33
Beijing 31
Princeton 28
Nanjing 22
Dearborn 17
Phoenix 14
Boardman 13
San Diego 13
Dong Ket 11
Nanchang 8
San Mateo 7
Shanghai 7
Fremont 6
Helsinki 6
Milan 6
Paris 6
Shenyang 6
Hebei 5
Izmir 5
Jinan 5
Tianjin 5
Brno 4
Changsha 4
Düsseldorf 4
Moscow 4
Munich 4
Norwalk 4
Venezia 4
Jiaxing 3
London 3
Málaga 3
Brussels 2
Lancaster 2
Manchester 2
Padova 2
San Francisco 2
Taizhou 2
Utrecht 2
Washington 2
Yenibosna 2
Zanjan 2
Agliana 1
Amman 1
Baghdad 1
Chiswick 1
Clearwater 1
Dhaka 1
Dubai 1
Edinburgh 1
Frankfurt am Main 1
Garching 1
Groningen 1
Haifa 1
Hefei 1
Hong Kong 1
Hounslow 1
Kunming 1
Los Angeles 1
Madrid 1
Manila 1
Mestre 1
Ningbo 1
Oklahoma City 1
Olomouc 1
Poggibonsi 1
Prague 1
Prescot 1
Quzhou 1
Redwood City 1
Singapore 1
Sucre 1
São Paulo 1
Tokyo 1
Winnipeg 1
Xian 1
Zhengzhou 1
Totale 1.875
Nome #
Prodrugs of pyrazolo[3,4-d]pyrimidines: from library synthesis to evaluation as potential anticancer agents in an orthotopic glioblastoma model 259
A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor 210
Pyrazolo[3,4-d]pyrimidines-loaded human serum albumin (HSA) nanoparticles: preparation, characterization and cytotoxicity evaluation against neuroblastoma cell line 203
4,6-Diphenylpyridines as Promising Novel Anti-Influenza Agents Targeting the PA-PB1 Protein-Protein Interaction: Structure-Activity Relationships Exploration with the Aid of Molecular Modeling 186
Combining X-ray Crystallography and Molecular Modeling toward the Optimization of Pyrazolo[3,4-d]pyrimidines as Potent c-Src Inhibitors Active in Vivo against Neuroblastoma. 186
Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant 155
Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment 150
Synthesis and biological evaluation of a library of hybrid derivatives as inhibitors of influenza virus PA-PB1 interaction 146
Protein-protein interactions and human cellular cofactors as new targets for HIV therapy 133
Insight into the Allosteric Inhibition of Abl Kinase 132
Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors 112
Inhibitors of tau-phosphorylating kinases 112
One-pot synthesis of spiro(indoline-3,4′-pyrazolo[3,4-b]pyridine)-5′-carbonitriles as p53-MDM2 interaction inhibitors 103
Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines 99
null 82
3-Arylidene-N-hydroxyoxindoles: A New Class of Compounds Endowed with Antitumor Activity 39
Totale 2.307
Categoria #
all - tutte 6.411
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.411


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020601 72 25 36 86 49 54 59 71 56 42 25 26
2020/2021330 9 35 6 33 19 41 12 48 23 53 24 27
2021/2022264 26 39 8 5 13 3 16 4 14 44 37 55
2022/2023315 18 41 33 40 35 49 13 27 38 9 9 3
2023/2024302 10 4 14 17 8 94 97 23 0 7 17 11
2024/20258 8 0 0 0 0 0 0 0 0 0 0 0
Totale 2.307